Activation of ERK1/2 MAP kinases in Familial Amyloidotic Polyneuropathy

Familial amyloidotic polyneuropathy (FAP) is a neurodegenerative disorder characterized by the extracellular deposition of transthyretin (TTR), especially in the PNS. Given the invasiveness of nerve biopsy, salivary glands (SG) from FAP patients were used previously in microarray analysis; mitogen‐activated protein (MAP) kinase phosphatase 1 (MKP‐1) was down‐regulated in FAP. Results were validated by RT‐PCR and immunohistochemistry both in SG and in nerve biopsies of different stages of disease progression. MKP‐3 was also down‐regulated in FAP SG biopsies. Given the relationship between MKPs and MAPKs, the latter were investigated. Only extracellular signal‐regulated kinases 1/2 (ERK1/2) displayed increased activation in FAP SG and nerves. ERK1/2 kinase (MEK1/2) activation was also up‐regulated in FAP nerves. In addition, an FAP transgenic mouse model revealed increased ERK1/2 activation in peripheral nerve affected with TTR deposition when compared to control animals. Cultured rat Schwannoma cell line treatment with TTR aggregates stimulated ERK1/2 activation, which was partially mediated by the receptor for advanced glycation end‐products (RAGE). Moreover, caspase‐3 activation triggered by TTR aggregates was abrogated by U0126, a MEK1/2 inhibitor, indicating that ERK1/2 activation is essential for TTR aggregates‐induced cytotoxicity. Taken together, these data suggest that abnormally sustained activation of ERK in FAP may represent an early signaling cascade leading to neurodegeneration.

[1]  P. Hofer,et al.  Postmortem findings in primary familial amyloidosis with polyneuropathy. , 2009, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[2]  W. Blaner,et al.  Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. , 1997, The American journal of pathology.

[3]  S. Nishiguchi,et al.  Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  N. Tonks.  PTP1B: From the sidelines to the front lines! , 2003, FEBS letters.

[5]  T. Oury,et al.  Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. , 2002, The American journal of pathology.

[6]  N. Yanagisawa,et al.  Peripheral nerve pathological findings in familial amyloid polyneuropathy: A correlative study of proximal sciatic nerve and sural nerve lesions , 1989, Annals of neurology.

[7]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[8]  K. Isobe,et al.  Mitogen-activated protein kinase pathway mediates peroxynitrite-induced apoptosis in human dopaminergic neuroblastoma SH-SY5Y cells. , 1999, Biochemical and biophysical research communications.

[9]  Yasuyoshi Watanabe,et al.  Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons , 2000, Neuroscience Letters.

[10]  Y. Sakaki,et al.  Comparison of amyloid deposition in two lines of transgenic mouse that model familial amyloidotic polyneuropathy, type I , 1997, Transgenic Research.

[11]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[12]  C. Chu,et al.  Sustained extracellular signal‐regulated kinase activation by 6‐hydroxydopamine: implications for Parkinson's disease , 2001, Journal of neurochemistry.

[13]  M. Saraste,et al.  FEBS Lett , 2000 .

[14]  A. Brouwer,et al.  Thyroxine binding to transthyretin Met 119 , 1997, Endocrine.

[15]  Jon W. Johnson,et al.  Persistent Activation of ERK Contributes to Glutamate-induced Oxidative Toxicity in a Neuronal Cell Line and Primary Cortical Neuron Cultures* , 2000, The Journal of Biological Chemistry.

[16]  Jia-Ren Lin,et al.  Bidirectional signals transduced by DAPK–ERK interaction promote the apoptotic effect of DAPK , 2005, The EMBO journal.

[17]  W. Trojaborg,et al.  RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  M. Moskowitz,et al.  MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Y. Kimura,et al.  Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: a clinicopathologic, histochemical, immunohistochemical, and ultrastructural study. , 1991, Human pathology.

[20]  A. Schmidt,et al.  Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.

[21]  N. Ito,et al.  Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. , 1987, Brain : a journal of neurology.

[22]  H. Huttunen,et al.  Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.

[23]  H. Braak,et al.  Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. , 2002, Brain research. Molecular brain research.

[24]  M. Sousa,et al.  Up‐regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase‐associated lipocalin and matrix metalloproteinase‐9 in familial amyloid polyneuropathy , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  M. Nakajima,et al.  The receptor for advanced glycation end‐products (RAGE) directly binds to ERK by a D‐domain‐like docking site , 2003, FEBS letters.

[26]  M. Sousa,et al.  Familial Amyloid Polyneuropathy: Receptor for Advanced Glycation End Products-Dependent Triggering of Neuronal Inflammatory and Apoptotic Pathways , 2001, The Journal of Neuroscience.

[27]  A. Brouwer,et al.  Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. , 1997, Endocrine.

[28]  Toshiyuki Fukada,et al.  Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. , 2002, Molecular cell.

[29]  T. Kislinger,et al.  Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.

[30]  S. Grewal,et al.  Extracellular-signal-regulated kinase signalling in neurons , 1999, Current Opinion in Neurobiology.

[31]  A. Schmidt,et al.  Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.

[32]  C. Andrade,et al.  Familial amyloid polyneuropathy: an electron microscope study of the peripheral nerve in five cases. II. Nerve fibre changes. , 1971, Brain : a journal of neurology.

[33]  M. Sousa,et al.  Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. , 2001, The American journal of pathology.

[34]  INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .

[35]  M. Moskowitz,et al.  Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Sousa,et al.  Interaction of the Receptor for Advanced Glycation End Products (RAGE) with Transthyretin Triggers Nuclear Transcription Factor kB (NF-kB) Activation , 2000, Laboratory Investigation.

[37]  M. Camps,et al.  Dual specificity phosphatases: a gene family for control of MAP kinase function , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  Carla Perrone-Capano,et al.  Chronic activation of ERK and neurodegenerative diseases , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[39]  C. Andrade,et al.  Familial amyloid polyneuropathy: an electron microscope study of the peripheral nerve in five cases. I. Interstitial changes. , 1971, Brain : a journal of neurology.

[40]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.